In plain terms

The claim being assessed: Replacing cis-unsaturated dietary fats with saturated fats causally increases ASCVD risk through elevation of LDL/apoB particles.

Where the evidence stands: Ε — Causal in a specific setting. It genuinely causes the effect in one well-defined situation, but that does not extend to the wider claim.

What this mechanism does: This makes the process worse or keeps it going, but something else starts it.

Strongest evidence for it: Overall Ε follows preregistered SC3. The isolated biomarker component is Γ and the independently convergent particle-to-ASCVD component is Η. SC3 is assessed on their assembled complementary evidence with clinical dietary results, not by reimposing the biomarker cap on the whole set. Comparator-specific effects, historical endpoint conflicts, food matrix and uncertain selective mediation prevent broad diet-specific Ζ. This remains a bounded reviewer judgement, not a numerical estimate of individual risk.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Alternative ranked ahead

What this review means

Saturated-for-cis-unsaturated replacement can raise LDL/apoB and is expected to raise ASCVD risk; the net clinical effect depends on the replacement, food matrix and exposure context.

Implications for health and treatment: Overall Ε follows preregistered SC3. The isolated biomarker component is Γ and the independently convergent particle-to-ASCVD component is Η. SC3 is assessed on their assembled complementary evidence with clinical dietary results, not by reimposing the biomarker cap on the whole set. Comparator-specific effects, historical endpoint conflicts, food matrix and uncertain selective mediation prevent broad diet-specific Ζ. This remains a bounded reviewer judgement, not a numerical estimate of individual risk.

Limits for individual care: 53 primary reports with 4 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 53 primary reports; claims: 57; verified: 57; unverified: 0. Verification is bounded attribution. Access: 4 partial-body and 49 bounded abstract/status examinations. Literature cutoff: 2026-10-09; source examination UTC date: 2026-10-12. No complete-paper audit or blinded calibration claimed.

Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 2 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

Saturated-for-cis-unsaturated replacement can raise LDL/apoB and is expected to raise ASCVD risk; the net clinical effect depends on the replacement, food matrix and exposure context.

Deciding experiment: Independently run, preregistered long-term isoenergetic replacement trial with fixed SFA species, cis-PUFA/cis-MUFA comparators, matched food matrices, trans-fat measurement, sustained apoB separation and blinded adjudicated ASCVD outcomes; prospectively test mediation and competing metabolic pathways.

Belief versus evidence: Overall Ε follows preregistered SC3. The isolated biomarker component is Γ and the independently convergent particle-to-ASCVD component is Η. SC3 is assessed on their assembled complementary evidence with clinical dietary results, not by reimposing the biomarker cap on the whole set. Comparator-specific effects, historical endpoint conflicts, food matrix and uncertain selective mediation prevent broad diet-specific Ζ. This remains a bounded reviewer judgement, not a numerical estimate of individual risk.

Best-supported rival: Replacement-nutrient and food-matrix model. The randomized coconut/olive/butter comparison (PMID29511019) and palm/cocoa-butter comparison (PMID31227804) best discriminate matrix-specific lipid effects from a uniform saturated-fat-class model. Neither supplies a clinical-event separator. DIVAS (PMID26016869) separates lipid benefit from its null primary vascular endpoint, while particle trials establish a different causal link.

COMPETING MECHANISTIC MODELS

Rank 1: Replacement-nutrient and food-matrix model (Ε). Net risk depends on which foods/fatty acids replace which nutrients, with the particle pathway as a causal component. Feeding heterogeneity, substitution cohorts and dietary endpoint contrasts explain comparator-specific effects. No complete food-specific causal map or selective clinical mediation estimate exists.

Rank 2: Saturated-fat–LDL risk model (Ε). Sustained SFA-for-cis-UFA replacement elevates particles and thereby contributes to ASCVD. Controlled lipid effects and independent particle-lowering/genetic clinical evidence strongly support the causal chain. Uniform net effects and diet-specific attribution are weaker than particle causality.

Rank 3: LDL-independent dietary pathways (Γ). Foods also act through weight, metabolism, inflammation and other pathways. Multifactor interventions and metabolic responses provide plausible additional routes. Those routes do not make apoB particles noncausal and are incompletely isolated.

Rank 4: Observational-confounding explanation (Β). Dietary associations reflect socioeconomic and behavioural confounding. Cohorts and adherence analyses have substantial shared vulnerabilities. Confounding alone does not explain controlled feeding and randomized particle-lowering clinical effects.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Replacing cis-unsaturated dietary fats with saturated fats causally increases ASCVD risk through elevation of LDL/apoB particles.

SC3 is the clinical causal claim at the registered scope; narrower molecular, treatment or inherited-syndrome findings cannot replace it. Primary-subclaim aggregation is fixed before grading.

Selection: remaining-priority list position 7 from the editorial list of 2026-10-09. Registered claim assessed against original sources. This is not independent blinded calibration.

Evidence and causal interpretation

Rubric fit: 06-metabolism-aging is the registered closest rubric, although ASCVD nutrition is not a lifespan hypothesis. Its functional endpoint is explicitly operationalized as clinical ASCVD rather than requiring lifespan extension. SC1 alone remains biomarker-limited; SC2 clinical events and SC3 assembled dietary/particle inference receive separate adjudication. The adaptation is visible and should receive independent reviewer scrutiny.

Controlled feeding provides reproducible lipid direction but heterogeneous magnitudes. DIVAS improves LDL while its primary vascular-function outcome is null; its projected mortality improvement is a model, not observed clinical deaths. RISSCI-1 shows marked response variation and is explicitly nonrandomized sequential, despite appearing in a general feeding-evidence category in Consensus. [51] [52]

The particle-to-ASCVD link is stronger and independently causal. Randomized PCSK9 interventions reduce events in secondary prevention and selected people without prior MI/stroke. MR prioritizes apoB while showing LDL/remnant/Lp(a) particles are not interchangeable. Achieved-LDL follow-ups are not independent randomizations or randomized mediation. [25] [26] [27] [14] [16] [19] [20]

Dietary endpoint results deserve separate weight. Finnish hospital and Oslo/Lyon programs suggest benefit but change multiple exposures. PREDIMED uses a corrected republished analysis after allocation departures, and compares dietary patterns with reduced-fat advice. These do not measure a pure isolated SFA-for-cis-UFA clinical treatment effect. [2] [6] [33] [49]

Minnesota and Sydney are retained as opposing evidence. The recovered analyses contain original participant-data analyses and are counted for those components only; their embedded systematic reviews do not pad the primary count. Minnesota follow-up was restricted to inpatient exposure and complete raw mortality data were unavailable; its 2024 correction repairs a thesis link. Sydney authors consider trans-fat changes unlikely to explain their result, but acknowledge inadequate data to exclude nutrient cochanges. Contamination is a limitation, not a proved dismissal. [32] [48] [50]

Replacement matters in cohort and feeding results. PURE and carbohydrate/avocado comparisons address different contrasts from the fixed cis-UFA question. Dairy/meat SFA and coconut/butter differ; healthy-food matrix effects can oppose simplistic fat-class predictions. RISSCI-2 selects previous responders and shares screening recruitment, so it cannot silently redefine a general-population claim. [11] [12] [37] [40] [45] [47] [53]

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Subclaim matrix and aggregation

Preregistered aggregation: primary-subclaim. Overall Ε follows preregistered SC3. The isolated biomarker component is Γ and the independently convergent particle-to-ASCVD component is Η. SC3 is assessed on their assembled complementary evidence with clinical dietary results, not by reimposing the biomarker cap on the whole set. Comparator-specific effects, historical endpoint conflicts, food matrix and uncertain selective mediation prevent broad diet-specific Ζ. This remains a bounded reviewer judgement, not a numerical estimate of individual risk. Sensitivities: weakest-link Γ; primary-subclaim Ε; scope-matched Ε.

Decisive-perturbation inventory and causal tally

[14] Multivariable MR prioritizes apoB for CHD over correlated lipid measures. Instrument validity, collinearity and shared GWAS restrict exclusive mediation interpretation.

[16] LPL and LDLR genetic scores yield similar lower CHD risk per apoB decrement despite differing cholesterol/triglyceride effects. Lifelong genetic exposure and pleiotropy; does not estimate a food-substitution treatment effect.

[25] Randomized evolocumab reduces LDL and major cardiovascular events on statin background. Drug strategy rather than diet; limited duration and residual risk preclude universal necessity/sufficiency.

[26] Randomized alirocumab reduces clinical events after acute coronary syndrome. PCSK9 drug class shares mechanistic vulnerabilities with evolocumab; not direct SFA exchange.

[27] Evolocumab reduces first cardiovascular-event composites in selected high-risk patients without prior MI/stroke. High-risk disease/diabetes eligibility and mostly White participants; not universal primary prevention or a feeding trial.

[48] Recovered Sydney trial data show greater mortality under the linoleic-acid replacement intervention. Primary participant-data reanalysis only; original protocol and precise trans-fat exposure unavailable, and linked erratum details not examined.

[49] Corrected PREDIMED analysis retains lower cardiovascular events for olive-oil/nut Mediterranean diets. Allocation departures and adjusted reanalysis; multifactor diet versus reduced-fat advice does not isolate the nominal exchange.

[50] Recovered Minnesota trial data confirm cholesterol lowering without mortality benefit. Primary trial reanalysis only; incomplete raw recovery and inpatient exposure. The 2024 correction repairs a thesis link, not results.

Tally: 8 positive qualifying study units across scoped subclaims; 37 screened discriminating contrast units. These are not independent causal lines or proof of full-claim necessity/sufficiency. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Reports sharing recruitment, instruments or randomization are not automatically independent causal lines. The tally includes discriminating contrasts; positive qualifying source lists alone determine threshold crossings.

Cap audit, precedence and Β/Γ/Δ boundary

The biomarker-only cap binds isolated SC1 and dietary LDL-only evidence offered as direct event proof. It is not reapplied to the complementary human genetic plus randomized clinical SC2 set. SC3 uses that set with clinical dietary intervention and substitution evidence; it cannot inherit Η wholesale because diet-specific net effects and selective mediation retain shared confounders. Carbohydrate and trans-fat comparisons do not silently replace the registered cis-unsaturated comparator.

Universal six-cap audit: All six universal caps were considered. Cell-only evidence is bounded by cap 1; unperturbed associations by cap 2; ectopic models by cap 3; biomarker-only trials by cap 4. Cap 5 binds only forced-transfer inference. Cap 6 restricts inherited-syndrome transfer to sporadic scope. Each binds the offered inference, not an independently convergent same-scope causal set.

Gamma hard-rule audit: Abstract association, cellular rescue and biomarker response alone do not demonstrate the registered human clinical claim. Positive narrow perturbations retain their scope; null studies do not earn positive threshold crossings.

SC1 cap: “Biomarker change without functional/phenotypic change caps at Γ.” Controlled feeding demonstrates a real biochemical LDL/apoB response, with heterogeneous responses across food matrices and comparators. The isolated SC1 evidence has biomarker endpoints, so the aging rubric functional-phenotype ceiling is Γ; this letter does not deny causality of the measured lipid response.

SC1 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Controlled feeding demonstrates a real biochemical LDL/apoB response, with heterogeneous responses across food matrices and comparators. The isolated SC1 evidence has biomarker endpoints, so the aging rubric functional-phenotype ceiling is Γ; this letter does not deny causality of the measured lipid response.

SC2 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: yes. Randomized clinical particle-lowering, human causal genetics and lifelong hypercholesterolemia converge on apoB-particle contribution to ASCVD. Different genotypes, drug strategies and clinical settings constrain distinct errors. Dietary trial conflicts do not overturn this independently supported causal component.

SC3 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: yes. The assembled replacement, particle-causal and clinical-dietary evidence supports context-specific particle-mediated risk. It is stronger than biomarkers alone when read as a complementary causal set, but direct diet-specific clinical mediation, universal food-class effects and equally supported MUFA/PUFA event benefits remain unresolved. Clinical dietary patterns and historical replacements map restricted context rather than a universal guaranteed outcome.

Upward threshold ladder

SC1 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Functional clinical outcomes linked to the measured particle change are required to exceed its isolated biomarker ceiling; the complementary SC2 set supplies that broader clinical link.

SC2 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: yes.

SC2 Ε: “Requires causal effect in constrained contexts, backgrounds, or species.” Satisfied: yes.

SC2 Ζ: “Requires: - Reproducible intervention effects - Mechanistic narrowing - Evidence not reducible to general sickness, caloric reduction, or developmental artifacts” Satisfied: yes.

SC2 Η: “Requires: - Robust cross-context intervention evidence - Mechanistic specificity - Strong alignment of lifespan/healthspan outcomes” Satisfied: yes.

SC2 Θ: “Requires high reproducibility with minimal contextual contradiction.” Satisfied: no. Further independent selective perturbation with prespecified particle-mediated clinical prediction, stable applicability across risk/ancestry and explicit residual-risk accounting would support Θ; neither universal necessity nor sufficiency is shown.

SC3 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: yes.

SC3 Ε: “Requires causal effect in constrained contexts, backgrounds, or species.” Satisfied: yes.

SC3 Ζ: “Requires: - Reproducible intervention effects - Mechanistic narrowing - Evidence not reducible to general sickness, caloric reduction, or developmental artifacts” Satisfied: no. A well-controlled long-term isoenergetic SFA-for-cis-UFA trial, specified fatty-acid species and food matrices, verified sustained apoB separation and adjudicated ASCVD events, with independent replication and prespecified mediation, would narrow major alternatives sufficiently for Ζ.

Upper ladder: Human MR, lifelong exposure and randomized clinical perturbation support Η for SC2 despite individual observational weaknesses. Shared UK Biobank/GWAS and PCSK9 class dependencies are retained. SC3 lacks equally independent, selective diet-specific clinical mediation across predetermined replacements and matrices; this scope gap prevents Ζ without downgrading the independent particle causal set.

Independence: FOURIER and its achieved-LDL/extension reports share randomization or selected follow-up; they are one program, not four independent trials. Minnesota reanalyses share the original cohort. STRIP and RISSCI follow-ups share participants. US nutrition cohorts and UK Biobank/GWAS resources share dietary measurement or genetic assumptions. Genetics, feeding and clinical drug trials constrain different errors; none proves all dietary net effects alone.

Controlled dietary exposure [51, 45, 40]: Constrains nutrient-reporting and treatment-selection error, but trials are short and food changes can be pleiotropic.

Inherited particle-pathway contrasts [16, 14, 29]: Constrains reverse clinical causation and short-term adherence; pleiotropy, selection and shared cohorts remain.

Randomized clinical particle lowering [25, 26, 27]: Constrains allocation and outcome confounding, with measured LDL and clinical events; related drug classes share off-target assumptions.

Clinical dietary interventions [2, 50, 48, 49]: Measures clinical net effects directly, but matrix, adherence, allocation/recovery and multiple nutrients constrain selective attribution.

Falsification and pitfalls

Biomarker improvement without the proposed clinical benefit. Minnesota and DIVAS retain null clinical/vascular endpoints despite cholesterol lowering; effects constrain universality without re-capping independent SC2. Additional downgrade: False.

Primary clinical mediation inferred from a lipid-only endpoint. SC1 and short feeding studies; DIVAS projected mortality.

Wrong replacement comparator. Carbohydrate, trans-fat and multicomponent-diet results do not equal fixed cis-UFA exchange.

Shared cohort reports counted as independent causal lines. FOURIER, STRIP, Minnesota, RISSCI and repeated GWAS resources.

Adversarial steelman: above, then below

One rung above, Ζ: randomized feeding, natural genetics, drug clinical outcomes and multiple diet programs are orthogonal. Together they warrant causal risk expectation. However, independent same-scope selective dietary clinical mediation is not established across matrices and both cis-UFA classes; endpoint conflicts and shared historical-trial limitations leave major alternatives open.

One rung below, Δ: only a first contribution has been shown and direct selective feeding-event proof is weak. Yet the biochemical-to-clinical chain has independent human causal support, multiple clinical dietary contexts and mapped comparator boundaries. Ε better represents causal operation with constrained generalization, while the assignment remains less secure than SC2.

Retain Ε for assembled SC3; reject automatic transfer to Ζ and reject biomarker-only Γ as a description of the entire complementary clinical causal set.

Final score, causal direction and M/S/D

Overall Ε follows preregistered SC3. The isolated biomarker component is Γ and the independently convergent particle-to-ASCVD component is Η. SC3 is assessed on their assembled complementary evidence with clinical dietary results, not by reimposing the biomarker cap on the whole set. Comparator-specific effects, historical endpoint conflicts, food matrix and uncertain selective mediation prevent broad diet-specific Ζ. This remains a bounded reviewer judgement, not a numerical estimate of individual risk.

Dietary exposure changes lipids and clinical risk, so it is not solely a downstream marker or co-occurrence. Replacing this exposure neither prevents all ASCVD nor has proven universal initiating/rate-limiting status; familial, metabolic and other risks persist. It is not universally required. Step 5 assigns a modifiable amplifier of atherosclerotic risk, not a sole primary cause.

Momentum: Mechanistic only. RISSCI-2 (PMID42664559, 2026) tests absorption as a response mechanism and does not find it explains the high/low-response contrast. VESALIUS-CV (PMID41211925) extends clinical particle lowering to a different risk population. Neither is a new selective dietary mediation trial crossing SC3 to Ζ.

Stability: Stable. No verified named pending result that would change the registered full-scope grade was identified. This does not mean that no relevant trial exists.

Divergence: Contested. No manufactured field consensus or arithmetic gap. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

Independently run, preregistered long-term isoenergetic replacement trial with fixed SFA species, cis-PUFA/cis-MUFA comparators, matched food matrices, trans-fat measurement, sustained apoB separation and blinded adjudicated ASCVD outcomes; prospectively test mediation and competing metabolic pathways.

Readout: Adjudicated ASCVD events and prespecified exposure/apoB-mediated risk differences. Controls: Energy balance, food matrix, adherence, medications, cis/trans composition, unbiased allocation and outcome assessment. Supporting: Replicated clinical event separation aligned with sustained particle differences under the specified replacement. Falsifying: Adequate sustained exposure and apoB separation with precise absent or opposite event effect, or benefits explained by prespecified nonparticle pathways.

KNOWLEDGE GAPS

Selective diet-specific clinical mediation remains weaker than particle causality.

Cis-MUFA and cis-PUFA, individual SFA species and food matrices need separate effect estimates.

Historical trans-fat exposure and incomplete data recovery remain unresolved; contamination must not be asserted as an established explanation of nulls.

Mean response and responder-defined follow-up are distinct populations.

More diverse clinical populations and complete correction/supplement checks are needed.

REVIEWER NOTES

Bounded original primary abstract/status passages and selected original body sections were examined. Supplements and most complete papers were not audited. Consensus browser synthesis is supplementary and does not count as primary evidence. Scite anchor tallies/outgoing contexts and SciSpace discovery were examined as supplementary inputs. No independent blinded grading is claimed.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

Consensus and original-source reconciliation

Original DIVAS abstract reports beneficial lipid changes but a null primary vascular-function comparison. A projected mortality reduction is a risk calculation, not observed trial deaths. PMID 26016869.

Original primary abstract describes a nonrandomized sequential dietary design. Average LDL/apoB reduction is informative but does not become a randomized event-endpoint trial. PMID 39111551.

Original RISSCI-2 abstract uses participants selected on prior response and does not establish absorption as the explanation. It is not an independent population replication of RISSCI-1. PMID 42664559.

Original Minnesota reanalysis body separates cholesterol lowering from its clinical mortality result and incomplete historical follow-up. The linked 2024 correction repairs a thesis link; it does not reverse the results. PMID 27071971.

Original Sydney body reports unmeasured trans-fat exposure and other dietary uncertainties. They cannot be discarded as proven trans-fat contamination. PMID 23386268.

Consensus was used to identify literature and cross-check specific claims about study design, endpoints, scope and research gaps. Those claims were checked against original primary abstracts/status records and, for selected studies, original Methods or Results passages. Consensus output was not treated as original full text. Source-specific access depth and receipts are retained. Scite supplied one five-anchor citation-context/tally query; returned contexts were outgoing references, not an audited incoming contradiction set. SciSpace supplied one discovery pass; it added no primary-count credit.

Research timeline and gap priorities

Selected publication milestones through 9 October 2026. These dates identify source publication years, not priority claims or a comprehensive history.

1979 — Finnish hospital dietary periods test cholesterol and coronary outcomes in a limited historical design. PMID 393644.

1989 — Original Minnesota trial clinical report; one parent study with the later reanalysis. PMID 2643423.

2013 — Recovered Sydney trial data sharpen uncertainty about intervention composition and mortality. PMID 23386268.

2016 — Recovered Minnesota data distinguish lipid response from observed mortality. PMID 27071971.

2017 — FOURIER tests pharmacological LDL lowering with clinical event endpoints. PMID 28304224.

2020 — Multivariable genetics prioritizes apoB across correlated lipid measures. PMID 32203549.

2024 — RISSCI-1 documents heterogeneous responses in a sequential design. PMID 39111551.

2026 — Response-selected RISSCI-2 examines a proposed absorption explanation. PMID 42664559.

Research gaps

Selective diet-specific clinical mediation remains weaker than particle causality.

Cis-MUFA and cis-PUFA, individual SFA species and food matrices need separate effect estimates.

Historical trans-fat exposure and incomplete data recovery remain unresolved; contamination must not be asserted as an established explanation of nulls.

Mean response and responder-defined follow-up are distinct populations.

More diverse clinical populations and complete correction/supplement checks are needed.

Study that would resolve the boundary

Independently run, preregistered long-term isoenergetic replacement trial with fixed SFA species, cis-PUFA/cis-MUFA comparators, matched food matrices, trans-fat measurement, sustained apoB separation and blinded adjudicated ASCVD outcomes; prospectively test mediation and competing metabolic pathways.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14.

Scope of checks: all 53 REFERENCES PMIDs verified against PubMed metadata (53/53 resolved to the stated title, first author, journal and year; no retraction or expression-of-concern notices; the five linked errata are recorded in parent-source status flags rather than as numbered sources); 12 load-bearing claims spot-checked against the cited abstracts; scoring logic re-derived against references/hsef-framework.md and SKILL.md Steps 2-3, 11 and 12 (six universal caps and cap precedence, primary-subclaim aggregation, independence basis for the Η subclaim, Β/Γ/Δ boundary, Momentum/Stability/Divergence artifacts).

Rejected findings (checked, no change): - Headline Ε at the registered diet-specific scope. Ζ requires reproducible effects plus mechanistic narrowing with major alternatives narrowed; the review documents that no long-term isoenergetic saturated-for-cis-unsaturated trial with adjudicated events and verified apoB separation exists, and that the historical replacement trials (Minnesota, Sydney) conflict with the dietary prediction. Γ would be wrong because it would reimpose the biomarker cap on a set that includes randomized particle-lowering outcome trials and human genetics. The framework's cap-precedence rule ("a universal cap governs the inference from that system to the hypothesis's claimed scope") supports grading the component SC2 at Η while holding the diet-specific SC3 at Ε. - Confidence "Moderate". Unlike the mainstream particle component, the diet-specific clinical literature is heterogeneous in direction and comparator, so "some assay-level concerns or methodological heterogeneity remains" fits better than the High band's "reproducibility well-established". The identical access-based confidence rationale appears across this batch and is noted for the lead, but the band itself is defensible here. - Momentum "Mechanistic only" carries its required artifact and names the work: RISSCI-2 (PMID 42664559) and VESALIUS-CV (PMID 41211925), neither of which is a selective dietary mediation trial. - Divergence "Contested" is appropriate where the field's framing genuinely splits between guideline statements and a dissenting literature, so no single implied level applies. - Primary-subclaim aggregation on SC3 returns Ε, and both alternatives are reported (weakest-link Γ, scope-matched Ε). - Minnesota and Sydney are retained as opposing evidence and are explicitly not dismissed as proven trans-fat contamination, while their embedded systematic reviews are excluded from the primary count — both correct treatments. - Numeric and design claims verified: DIVAS null primary flow-mediated dilatation with LDL cholesterol down 11.3% and 13.6% and a projected 17-20% mortality reduction (PMID 26016869); RISSCI-1 nonrandomized sequential design with LDL response ranging from -1.39 to +0.77 mmol/L (PMID 39111551); RISSCI-2 participants selected on prior response, with absorption not explaining the response difference (PMID 42664559); Minnesota cholesterol fall of 13.8% versus 1.0% with no mortality benefit (PMID 27071971); Sydney recovered data from 458 men in secondary prevention (PMID 23386268); butter versus coconut and olive oil LDL differences of +0.42 and +0.38 mmol/L (PMID 29511019); VESALIUS-CV 3-point MACE hazard ratio 0.75 in 12,257 patients without previous myocardial infarction or stroke, 93% White (PMID 41211925).

Residual limitations: access depth is unchanged at 4 partial-body and 49 abstract/status examinations; the five linked errata are recorded but their contents were not examined; the review's rubric routing to 06-metabolism-aging for an ASCVD nutrition claim remains an explicit adaptation and is flagged in the review itself for independent scrutiny.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.

REFERENCES

1. Laitinen TT, Nuotio J, Rovio SP et al. Dietary Fats and Atherosclerosis From Childhood to Adulthood. Pediatrics. 2020. PMID 32209700. DOI: 10.1542/peds.2019-2786. Access: abstract_metadata. Study: STRIP.

2. Turpeinen O, Karvonen MJ, Pekkarinen M et al. Dietary prevention of coronary heart disease: the Finnish Mental Hospital Study. International journal of epidemiology. 1979. PMID 393644. DOI: 10.1093/ije/8.2.99. Access: abstract_metadata. Study: PMID393644.

3. Laitinen TT, Nuotio J, Juonala M et al. Success in Achieving the Targets of the 20-Year Infancy-Onset Dietary Intervention: Association With Insulin Sensitivity and Serum Lipids. Diabetes care. 2018. PMID 30072407. DOI: 10.2337/dc18-0869. Access: abstract_metadata. Study: STRIP.

4. Grundy SM, Nix D, Whelan MF et al. Comparison of three cholesterol-lowering diets in normolipidemic men. JAMA. 1986. PMID 3773141. No DOI in the PubMed record. Access: abstract_metadata. Study: PMID3773141.

5. Fridén M, Rosqvist F, Kullberg J et al. Effects of an anti-lipogenic low-carbohydrate high polyunsaturated fat diet or a healthy Nordic diet versus usual care on liver fat and cardiometabolic disorders in type 2 diabetes or prediabetes: a randomized controlled trial (NAFLDiet). Nature communications. 2025. PMID 41390743. DOI: 10.1038/s41467-025-65613-2. Access: abstract_metadata. Study: PMID41390743.

6. Hjermann I, Holme I, Leren P. Oslo Study Diet and Antismoking Trial. Results after 102 months. The American journal of medicine. 1986. PMID 3511692. DOI: 10.1016/0002-9343(86)90154-3. Access: abstract_metadata. Study: PMID3511692.

7. Burén J, Ericsson M, Damasceno NRT et al. A Ketogenic Low-Carbohydrate High-Fat Diet Increases LDL Cholesterol in Healthy, Young, Normal-Weight Women: A Randomized Controlled Feeding Trial. Nutrients. 2021. PMID 33801247. DOI: 10.3390/nu13030814. Access: abstract_metadata. Study: PMID33801247.

8. Ebbeling CB, Knapp A, Johnson A et al. Effects of a low-carbohydrate diet on insulin-resistant dyslipoproteinemia-a randomized controlled feeding trial. The American journal of clinical nutrition. 2022. PMID 34582545. DOI: 10.1093/ajcn/nqab287. Access: abstract_metadata. Study: PMID34582545.

9. Stonehouse W, Benassi-Evans B, James-Martin G et al. Fatty acid regio-specificity of triacylglycerol molecules may affect plasma lipid responses to dietary fats-a randomised controlled cross-over trial. European journal of clinical nutrition. 2020. PMID 31227804. DOI: 10.1038/s41430-019-0452-7. Access: abstract_metadata. Study: PMID31227804.

10. Li Y, Hruby A, Bernstein AM et al. Saturated Fats Compared With Unsaturated Fats and Sources of Carbohydrates in Relation to Risk of Coronary Heart Disease: A Prospective Cohort Study. Journal of the American College of Cardiology. 2015. PMID 26429077. DOI: 10.1016/j.jacc.2015.07.055. Access: abstract_metadata. Study: PMID26429077.

11. Chen M, Li Y, Sun Q et al. Dairy fat and risk of cardiovascular disease in 3 cohorts of US adults. The American journal of clinical nutrition. 2016. PMID 27557656. DOI: 10.3945/ajcn.116.134460. Access: abstract_metadata. Study: PMID27557656.

12. Vissers LET, Rijksen J, Boer JMA et al. Fatty acids from dairy and meat and their association with risk of coronary heart disease. European journal of nutrition. 2019. PMID 30167851. DOI: 10.1007/s00394-018-1811-1. Access: abstract_metadata. Study: PMID30167851.

13. Arnesen EK, Laake I, Veierød MB et al. Saturated fatty acids and total and CVD mortality in Norway: a prospective cohort study with up to 45 years of follow-up. The British journal of nutrition. 2024. PMID 39279644. DOI: 10.1017/S0007114524001351. Access: abstract_metadata. Study: PMID39279644.

14. Richardson TG, Sanderson E, Palmer TM et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis. PLoS medicine. 2020. PMID 32203549. DOI: 10.1371/journal.pmed.1003062. Access: full_text_partial. Study: PMID32203549.

15. Zuber V, Gill D, Ala-Korpela M et al. High-throughput multivariable Mendelian randomization analysis prioritizes apolipoprotein B as key lipid risk factor for coronary artery disease. International journal of epidemiology. 2021. PMID 33130851. DOI: 10.1093/ije/dyaa216. Access: abstract_metadata. Study: PMID33130851.

16. Ference BA, Kastelein JJP, Ray KK et al. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA. 2019. PMID 30694319. DOI: 10.1001/jama.2018.20045. Access: abstract_metadata. Study: PMID30694319.

17. Yang G, Mason AM, Wood AM et al. Dose-Response Associations of Lipid Traits With Coronary Artery Disease and Mortality. JAMA network open. 2024. PMID 38241044. DOI: 10.1001/jamanetworkopen.2023.52572. Access: abstract_metadata. Study: PMID38241044.

18. Björnson E, Adiels M, Bergström G et al. The relationship between genetic liver fat and coronary heart disease is explained by apoB-containing lipoproteins. Atherosclerosis. 2024. PMID 38102060. DOI: 10.1016/j.atherosclerosis.2023.117397. Access: abstract_metadata. Study: PMID38102060.

19. Björnson E, Adiels M, Taskinen MR et al. Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis. Journal of the American College of Cardiology. 2024. PMID 38233012. DOI: 10.1016/j.jacc.2023.10.039. Access: abstract_metadata. Study: PMID38233012.

20. Björnson E, Adiels M, Taskinen MR et al. Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study. European heart journal. 2023. PMID 37358553. DOI: 10.1093/eurheartj/ehad337. Access: abstract_metadata. Study: PMID37358553.

21. Wang W, Li R, Song Z et al. Joint Associations of APOC3 and LDL-C-Lowering Variants With the Risk of Coronary Heart Disease. JAMA cardiology. 2025. PMID 40105833. DOI: 10.1001/jamacardio.2025.0195. Access: abstract_metadata. Study: PMID40105833.

22. O'Donoghue ML, Giugliano RP, Wiviott SD et al. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. Circulation. 2022. PMID 36031810. DOI: 10.1161/CIRCULATIONAHA.122.061620. Access: abstract_metadata. Study: FOURIER.

23. Kim BK, Hong SJ, Lee YJ et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet (London, England). 2022. PMID 35863366. DOI: 10.1016/S0140-6736(22)00916-3. Access: abstract_metadata. Study: PMID35863366.

24. Giugliano RP, Pedersen TR, Park JG et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet (London, England). 2017. PMID 28859947. DOI: 10.1016/S0140-6736(17)32290-0. Access: abstract_metadata. Study: FOURIER.

25. Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. The New England journal of medicine. 2017. PMID 28304224. DOI: 10.1056/NEJMoa1615664. Access: abstract_metadata. Study: FOURIER.

26. Schwartz GG, Steg PG, Szarek M et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. The New England journal of medicine. 2018. PMID 30403574. DOI: 10.1056/NEJMoa1801174. Access: abstract_metadata. Study: PMID30403574.

27. Bohula EA, Marston NA, Bhatia AK et al. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. The New England journal of medicine. 2026. PMID 41211925. DOI: 10.1056/NEJMoa2514428. Access: abstract_metadata. Study: PMID41211925.

28. Nicholls SJ, Puri R, Anderson T et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016. PMID 27846344. DOI: 10.1001/jama.2016.16951. Access: abstract_metadata. Study: PMID27846344.

29. Trinder M, Francis GA, Brunham LR. Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease. JAMA cardiology. 2020. PMID 32049305. DOI: 10.1001/jamacardio.2019.5954. Access: abstract_metadata. Study: PMID32049305.

30. Di Taranto MD, Giacobbe C, Palma D et al. Genetic spectrum of familial hypercholesterolemia and correlations with clinical expression: Implications for diagnosis improvement. Clinical genetics. 2021. PMID 34297352. DOI: 10.1111/cge.14036. Access: abstract_metadata. Study: PMID34297352.

31. Gaba P, O'Donoghue ML, Park JG et al. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Circulation. 2023. PMID 36779348. DOI: 10.1161/CIRCULATIONAHA.122.063399. Access: abstract_metadata. Study: FOURIER.

32. Frantz ID, Dawson EA, Ashman PL et al. Test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota Coronary Survey. Arteriosclerosis (Dallas, Tex.). 1989. PMID 2643423. DOI: 10.1161/01.atv.9.1.129. Access: abstract_metadata. Study: MINNESOTA.

33. de Lorgeril M, Salen P, Martin JL et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999. PMID 9989963. DOI: 10.1161/01.cir.99.6.779. Access: abstract_metadata. Study: PMID9989963.

34. Rosqvist F, Iggman D, Kullberg J et al. Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans. Diabetes. 2014. PMID 24550191. DOI: 10.2337/db13-1622. Access: abstract_metadata. Study: PMID24550191.

35. Chen CG, Wang P, Zhang ZQ et al. Effects of plant oils with different fatty acid composition on cardiovascular risk factors in moderately hypercholesteremic Chinese adults: a randomized, double-blinded, parallel-designed trial. Food & function. 2020. PMID 32756661. DOI: 10.1039/d0fo00875c. Access: abstract_metadata. Study: PMID32756661.

36. Carter S, Hill AM, Yandell C et al. Impact of dietary cholesterol from eggs and saturated fat on LDL cholesterol levels: a randomized cross-over study. The American journal of clinical nutrition. 2025. PMID 40339906. DOI: 10.1016/j.ajcnut.2025.05.001. Access: abstract_metadata. Study: PMID40339906.

37. Dehghan M, Mente A, Zhang X et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet (London, England). 2017. PMID 28864332. DOI: 10.1016/S0140-6736(17)32252-3. Access: abstract_metadata. Study: PMID28864332.

38. Ho FK, Gray SR, Welsh P et al. Associations of fat and carbohydrate intake with cardiovascular disease and mortality: prospective cohort study of UK Biobank participants. BMJ (Clinical research ed.). 2020. PMID 32188587. DOI: 10.1136/bmj.m688. Access: abstract_metadata. Study: PMID32188587.

39. Mah E, Schulz JA, Kaden VN et al. Cashew consumption reduces total and LDL cholesterol: a randomized, crossover, controlled-feeding trial. The American journal of clinical nutrition. 2017. PMID 28356271. DOI: 10.3945/ajcn.116.150037. Access: abstract_metadata. Study: PMID28356271.

40. Failor RA, Childs MT, Bierman EL. The effects of omega 3 and omega 6 fatty acid-enriched diets on plasma lipoproteins and apoproteins in familial combined hyperlipidemia. Metabolism: clinical and experimental. 1988. PMID 3185285. DOI: 10.1016/0026-0495(88)90061-3. Access: abstract_metadata. Study: PMID3185285.

41. Toobert DJ, Glasgow RE, Strycker LA et al. Biologic and quality-of-life outcomes from the Mediterranean Lifestyle Program: a randomized clinical trial. Diabetes care. 2003. PMID 12882850. DOI: 10.2337/diacare.26.8.2288. Access: abstract_metadata. Study: PMID12882850.

42. Quinn TG, Alderman EL, McMillan A et al. Development of new coronary atherosclerotic lesions during a 4-year multifactor risk reduction program: the Stanford Coronary Risk Intervention Project (SCRIP). Journal of the American College of Cardiology. 1994. PMID 7930223. DOI: 10.1016/0735-1097(94)90848-6. Access: abstract_metadata. Study: PMID7930223.

43. Jenkins DJ, Kendall CW, Popovich DG et al. Effect of a very-high-fiber vegetable, fruit, and nut diet on serum lipids and colonic function. Metabolism: clinical and experimental. 2001. PMID 11288049. DOI: 10.1053/meta.2001.21037. Access: abstract_metadata. Study: PMID11288049.

44. Denke MA, Frantz ID. Response to a cholesterol-lowering diet: efficacy is greater in hypercholesterolemic subjects even after adjustment for regression to the mean. The American journal of medicine. 1993. PMID 8506889. DOI: 10.1016/0002-9343(93)90215-b. Access: abstract_metadata. Study: PMID8506889.

45. Khaw KT, Sharp SJ, Finikarides L et al. Randomised trial of coconut oil, olive oil or butter on blood lipids and other cardiovascular risk factors in healthy men and women. BMJ open. 2018. PMID 29511019. DOI: 10.1136/bmjopen-2017-020167. Access: full_text_partial. Study: PMID29511019.

46. Wardlaw GM, Snook JT, Lin MC et al. Serum lipid and apolipoprotein concentrations in healthy men on diets enriched in either canola oil or safflower oil. The American journal of clinical nutrition. 1991. PMID 1905474. DOI: 10.1093/ajcn/54.1.104. Access: abstract_metadata. Study: PMID1905474.

47. Lerman-Garber I, Ichazo-Cerro S, Zamora-González J et al. Effect of a high-monounsaturated fat diet enriched with avocado in NIDDM patients. Diabetes care. 1994. PMID 8026287. DOI: 10.2337/diacare.17.4.311. Access: abstract_metadata. Study: PMID8026287.

48. Ramsden CE, Zamora D, Leelarthaepin B et al. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ (Clinical research ed.). 2013. PMID 23386268. DOI: 10.1136/bmj.e8707. Access: full_text_partial. Study: PMID23386268.

49. Estruch R, Ros E, Salas-Salvadó J et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. The New England journal of medicine. 2018. PMID 29897866. DOI: 10.1056/NEJMoa1800389. Access: abstract_metadata. Study: PMID29897866.

50. Ramsden CE, Zamora D, Majchrzak-Hong S et al. Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73). BMJ (Clinical research ed.). 2016. PMID 27071971. DOI: 10.1136/bmj.i1246. Access: full_text_partial. Study: MINNESOTA.

51. Vafeiadou K, Weech M, Altowaijri H et al. Replacement of saturated with unsaturated fats had no impact on vascular function but beneficial effects on lipid biomarkers, E-selectin, and blood pressure: results from the randomized, controlled Dietary Intervention and VAScular function (DIVAS) study. The American journal of clinical nutrition. 2015. PMID 26016869. DOI: 10.3945/ajcn.114.097089. Access: abstract_metadata. Study: PMID26016869.

52. Koutsos A, Griffin BA, Antoni R et al. Variation of LDL cholesterol in response to the replacement of saturated with unsaturated fatty acids: a nonrandomized, sequential dietary intervention; the Reading, Imperial, Surrey, Saturated fat Cholesterol Intervention ("RISSCI"-1) study. The American journal of clinical nutrition. 2024. PMID 39111551. DOI: 10.1016/j.ajcnut.2024.07.032. Access: abstract_metadata. Study: RISSCI.

53. Fielding BA, Koutsos A, Antoni R et al. Impact of saturated fat absorption on serum low density lipoprotein-cholesterol response to the replacement of saturated with unsaturated fats in healthy males. The 'Reading, Imperial, Surrey, Saturated fat Cholesterol Intervention-2 (RISSCI-2)' non-randomised sequential dietary intervention study. Atherosclerosis. 2026. PMID 42664559. DOI: 10.1016/j.atherosclerosis.2026.121884. Access: abstract_metadata. Study: RISSCI.

Source-specific evidence cards

[1] Dietary Fats and Atherosclerosis From Childhood to Adulthood.

Shows: Achieving STRIP dietary targets associates with better aortic structure and distensibility.

Does not show: Target attainment is not randomized; shared parent cohort and surrogate vascular outcomes.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[2] Dietary prevention of coronary heart disease: the Finnish Mental Hospital Study.

Shows: Finnish hospital diet periods with lower saturated fat/cholesterol show lower serum cholesterol and coronary incidence.

Does not show: Hospital-period crossover, changing admissions and multifactor diet prevent clean individual randomization or selective fat mediation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[3] Success in Achieving the Targets of the 20-Year Infancy-Onset Dietary Intervention: Association With Insulin Sensitivity and Serum Lipids.

Shows: STRIP target achievement associates with improved lipids and insulin sensitivity.

Does not show: Postrandomization adherence comparison; shares recruitment with PMID32209700 and changes fibre too.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[4] Comparison of three cholesterol-lowering diets in normolipidemic men.

Shows: Three replacement diets lower LDL in a small domiciliary feeding study.

Does not show: Very small sample; multiple macronutrient changes and no coronary endpoints.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[5] Effects of an anti-lipogenic low-carbohydrate high polyunsaturated fat diet or a healthy Nordic diet versus usual care on liver fat and cardiometabolic disorders in type 2 diabetes or prediabetes: a randomized controlled trial (NAFLDiet).

Shows: LCPUFA and Nordic diets reduce LDL and liver fat versus usual care in metabolic disease.

Does not show: Ad-libitum dietary patterns and differing weight changes; no selective saturated-fat clinical-outcome attribution.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[6] Oslo Study Diet and Antismoking Trial. Results after 102 months.

Shows: Oslo diet/antismoking intervention retains lower coronary-event rates on follow-up.

Does not show: Diet and smoking were changed together; clinical benefit is not exclusively saturated-fat replacement.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[7] A Ketogenic Low-Carbohydrate High-Fat Diet Increases LDL Cholesterol in Healthy, Young, Normal-Weight Women: A Randomized Controlled Feeding Trial.

Shows: Ketogenic high-fat feeding raises LDL and apoB in young normal-weight women.

Does not show: Carbohydrate, total fat and fatty-acid composition all change; incomplete retention and short duration.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[8] Effects of a low-carbohydrate diet on insulin-resistant dyslipoproteinemia-a randomized controlled feeding trial.

Shows: High-saturated-fat low-carbohydrate feeding improves selected lipid traits without an LDL increase versus comparators.

Does not show: Carbohydrate replacement differs from fixed cis-unsaturated replacement; linked correction details not examined.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID35022668. Subclaims: SC1.

[9] Fatty acid regio-specificity of triacylglycerol molecules may affect plasma lipid responses to dietary fats-a randomised controlled cross-over trial.

Shows: Palm/cocoa-butter and olive-oil diets have similar tested lipid responses in young participants.

Does not show: Fatty-acid positioning and limited sample/time constrain universal fat-class predictions.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[10] Saturated Fats Compared With Unsaturated Fats and Sources of Carbohydrates in Relation to Risk of Coronary Heart Disease: A Prospective Cohort Study.

Shows: Cohort substitution models associate replacing SFA with PUFA/MUFA with lower CHD risk.

Does not show: Diet-reporting, residual confounding and overlapping US cohorts; modeled exchange is not randomized.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[11] Dairy fat and risk of cardiovascular disease in 3 cohorts of US adults.

Shows: Dairy-fat substitution risk differs by replacement nutrient; PUFA replacement associates with lower CVD.

Does not show: Dairy versus carbohydrate is not the nominal comparison; overlaps US cohort resources.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[12] Fatty acids from dairy and meat and their association with risk of coronary heart disease.

Shows: Meat-versus-dairy SFA substitution associates with different coronary risk.

Does not show: Observational food-matrix differences and residual confounding; cannot isolate fatty acids alone.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[13] Saturated fatty acids and total and CVD mortality in Norway: a prospective cohort study with up to 45 years of follow-up.

Shows: Long-term Norwegian data associate higher SFA intake with mortality and model benefit of replacement.

Does not show: Measurement error, secular changes and residual confounding; theoretical exchange is not an intervention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[14] Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis.

Shows: Multivariable MR prioritizes apoB for CHD over correlated lipid measures.

Does not show: Instrument validity, collinearity and shared GWAS restrict exclusive mediation interpretation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 2:Results:paragraph7. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[15] High-throughput multivariable Mendelian randomization analysis prioritizes apolipoprotein B as key lipid risk factor for coronary artery disease.

Shows: Agnostic multivariable genetic analysis consistently prioritizes apoB for coronary disease.

Does not show: Shared genetic resources and instrument assumptions; not an independent dietary experiment.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[16] Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.

Shows: LPL and LDLR genetic scores yield similar lower CHD risk per apoB decrement despite differing cholesterol/triglyceride effects.

Does not show: Lifelong genetic exposure and pleiotropy; does not estimate a food-substitution treatment effect.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[17] Dose-Response Associations of Lipid Traits With Coronary Artery Disease and Mortality.

Shows: Genetically predicted apoB and LDL associate with coronary disease and mortality across dose ranges.

Does not show: Selection and nonlinear-MR assumptions; triglyceride pleiotropy and overlapping resources remain.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[18] The relationship between genetic liver fat and coronary heart disease is explained by apoB-containing lipoproteins.

Shows: Liver-fat genetic clusters show coronary-risk directions aligning with apoB changes.

Does not show: Statistical mediation and pleiotropy cannot establish all biological pathways or dietary specificity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[19] Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis.

Shows: Genetic analysis estimates greater CHD atherogenicity per Lp(a)-apoB particle than LDL-apoB.

Does not show: Particle types are not interchangeable; assumptions and populations constrain the magnitude estimate.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[20] Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study.

Shows: Remnant-associated genetic clusters show greater coronary-risk effects per apoB than LDL-associated clusters.

Does not show: Shared UK Biobank and differing pathways; not all apoB particles have equal risk weights.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[21] Joint Associations of APOC3 and LDL-C-Lowering Variants With the Risk of Coronary Heart Disease.

Shows: APOC3 and LDL-lowering genetic variants show additive CHD associations aligned with apoB.

Does not show: Drug-target genetic proxies are lifelong and partly pleiotropic; not randomized therapy or diet.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[22] Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.

Shows: FOURIER extension shows durable low LDL and lower events by original treatment allocation.

Does not show: Selected open-label extension with both groups treated; not a new independent randomization.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[23] Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.

Shows: RACING combination therapy is clinically noninferior to intensive statin with more LDL target attainment.

Does not show: Active-active noninferiority does not show benefit against untreated exposure or prove exclusive apoB mediation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[24] Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.

Shows: FOURIER achieved-LDL analysis shows a monotonic relation with later events.

Does not show: Achieved LDL is not randomized; shared parent randomization and selection after baseline.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[25] Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Shows: Randomized evolocumab reduces LDL and major cardiovascular events on statin background.

Does not show: Drug strategy rather than diet; limited duration and residual risk preclude universal necessity/sufficiency.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[26] Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Shows: Randomized alirocumab reduces clinical events after acute coronary syndrome.

Does not show: PCSK9 drug class shares mechanistic vulnerabilities with evolocumab; not direct SFA exchange.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[27] Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.

Shows: Evolocumab reduces first cardiovascular-event composites in selected high-risk patients without prior MI/stroke.

Does not show: High-risk disease/diabetes eligibility and mostly White participants; not universal primary prevention or a feeding trial.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[28] Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.

Shows: GLAGOV LDL lowering reduces coronary plaque volume and increases regression.

Does not show: Imaging phenotype is not clinical-event benefit; mechanistic support complements event trials.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[29] Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease.

Shows: Monogenic and polygenic hypercholesterolemia associate with higher ASCVD risk even at comparable measured LDL.

Does not show: Lifetime exposure differs from single measurement; selected genotype groups and linked erratum require caution.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID32159730. Subclaims: SC2.

[30] Genetic spectrum of familial hypercholesterolemia and correlations with clinical expression: Implications for diagnosis improvement.

Shows: FH variant severity tracks LDL patterns with substantial within-variant variation.

Does not show: Selected familial clinical sample; not a general-population diet intervention or sole causal line.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[31] Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE.

Shows: Lower achieved LDL in FOURIER-OLE associates with fewer subsequent clinical events.

Does not show: Postrandomization exposure, extension selection and shared cohort; not independent randomized dose assignment.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[32] Test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota Coronary Survey.

Shows: Minnesota dietary replacement lowers cholesterol without overall cardiovascular or mortality benefit.

Does not show: Limited inpatient exposure, dietary cholesterol changes and historical food composition; shares trial with PMID27071971.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[33] Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study.

Shows: Lyon Mediterranean dietary pattern retains lower recurrent cardiovascular complications.

Does not show: Multicomponent dietary pattern and secondary prevention; no selective saturated-fat/apoB mediation test.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[34] Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans.

Shows: Matched weight gain under SFA versus PUFA overfeeding produces different liver/visceral fat accumulation.

Does not show: Excess-calorie metabolic experiment, not ordinary-energy coronary-event replacement.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[35] Effects of plant oils with different fatty acid composition on cardiovascular risk factors in moderately hypercholesteremic Chinese adults: a randomized, double-blinded, parallel-designed trial.

Shows: Different plant cooking oils alter membrane composition without significant between-group lipid changes.

Does not show: All comparators are plant oils; no direct saturated-versus-cis-unsaturated contrast or clinical endpoints.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[36] Impact of dietary cholesterol from eggs and saturated fat on LDL cholesterol levels: a randomized cross-over study.

Shows: Low-SFA egg-containing feeding lowers LDL versus high-SFA control, with particle-subfraction changes.

Does not show: Eggs and fat composition change together; linked erratum not examined and no measured event reduction.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID41138747. Subclaims: SC1.

[37] Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study.

Shows: PURE associates higher fat intake with lower total mortality and no clear MI/CVD-mortality association.

Does not show: Carbohydrate comparison and socioeconomic/energy confounding differ from fixed cis-unsaturated replacement.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[38] Associations of fat and carbohydrate intake with cardiovascular disease and mortality: prospective cohort study of UK Biobank participants.

Shows: UK Biobank macronutrient associations are nonlinear and depend on intake range.

Does not show: Diet assessment and residual confounding; correction details not examined and cohort overlaps genetic analyses.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID32371385. Subclaims: SC3.

[39] Cashew consumption reduces total and LDL cholesterol: a randomized, crossover, controlled-feeding trial.

Shows: Cashew feeding lowers LDL relative to a potato-chip snack comparator.

Does not show: Carbohydrate/food-matrix replacement, not selective SFA exchange; short-term biomarkers.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[40] The effects of omega 3 and omega 6 fatty acid-enriched diets on plasma lipoproteins and apoproteins in familial combined hyperlipidemia.

Shows: Controlled safflower/salmon diets show lipid and apoB changes differing between normal and FCHL participants.

Does not show: Genotype and n-3/n-6 effects vary; no coronary endpoints or universal response.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[41] Biologic and quality-of-life outcomes from the Mediterranean Lifestyle Program: a randomized clinical trial.

Shows: Mediterranean lifestyle program improves glycemic control and quality of life with nonsignificant lipid patterns.

Does not show: Multicomponent lifestyle intervention cannot isolate dietary fat or particle-mediated ASCVD prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[42] Development of new coronary atherosclerotic lesions during a 4-year multifactor risk reduction program: the Stanford Coronary Risk Intervention Project (SCRIP).

Shows: SCRIP multifactor intervention shows a borderline lesion-level reduction and nonsignificant patient-level new-lesion difference.

Does not show: Multiple risk-factor treatments and correlated vessel segments; dietary correlation is not randomized mediation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[43] Effect of a very-high-fiber vegetable, fruit, and nut diet on serum lipids and colonic function.

Shows: Weight-maintaining high-fibre vegetable/fruit/nut diet lowers LDL and changes fecal steroid loss.

Does not show: Small short feeding study; fibre and food matrix prevent SFA-specific attribution or clinical-event inference.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[44] Response to a cholesterol-lowering diet: efficacy is greater in hypercholesterolemic subjects even after adjustment for regression to the mean.

Shows: Dietary cholesterol response differs by baseline cholesterol after accounting for regression toward the mean.

Does not show: Responsiveness analysis is not a selective randomized SFA comparison or clinical endpoint test.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[45] Randomised trial of coconut oil, olive oil or butter on blood lipids and other cardiovascular risk factors in healthy men and women.

Shows: Butter raises LDL relative to olive/coconut oils; coconut and olive responses do not differ significantly.

Does not show: Free-living addition or substitution, short duration and different SFA species; no clinical events.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph2, 1:Methods:paragraph3. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[46] Serum lipid and apolipoprotein concentrations in healthy men on diets enriched in either canola oil or safflower oil.

Shows: Canola/safflower diets reduce LDL and apoB versus initial American-diet baseline.

Does not show: Small sample and baseline-to-intervention order; not clinical-outcome evidence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[47] Effect of a high-monounsaturated fat diet enriched with avocado in NIDDM patients.

Shows: Avocado-rich MUFA replacement for carbohydrate improves selected lipids in diabetes.

Does not show: Carbohydrate comparator and food matrix differ from the fixed SFA replacement question.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[48] Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis.

Shows: Recovered Sydney trial data show greater mortality under the linoleic-acid replacement intervention.

Does not show: Primary participant-data reanalysis only; original protocol and precise trans-fat exposure unavailable, and linked erratum details not examined.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph1, 1:Methods:paragraph4, 3:Discussion:paragraph8, 3:Discussion:paragraph9, 3:Discussion:paragraph10, 3:Discussion:paragraph18, 3:Discussion:paragraph21. No complete-paper or supplement audit claimed. ErratumIn: PMIDnot supplied. Subclaims: SC1, SC3.

[49] Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts.

Shows: Corrected PREDIMED analysis retains lower cardiovascular events for olive-oil/nut Mediterranean diets.

Does not show: Allocation departures and adjusted reanalysis; multifactor diet versus reduced-fat advice does not isolate the nominal exchange.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[50] Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73).

Shows: Recovered Minnesota trial data confirm cholesterol lowering without mortality benefit.

Does not show: Primary trial reanalysis only; incomplete raw recovery and inpatient exposure. The 2024 correction repairs a thesis link, not results.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph6, 1:Methods:paragraph9, 2:Results:paragraph8. No complete-paper or supplement audit claimed. ErratumIn: PMID38942429. Subclaims: SC1, SC3.

[51] Replacement of saturated with unsaturated fats had no impact on vascular function but beneficial effects on lipid biomarkers, E-selectin, and blood pressure: results from the randomized, controlled Dietary Intervention and VAScular function (DIVAS) study.

Shows: Randomized isoenergetic DIVAS replacement reduces LDL but not its primary vascular-function endpoint.

Does not show: Estimated mortality reduction is modeled from lipid change, not observed deaths; short duration.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[52] Variation of LDL cholesterol in response to the replacement of saturated with unsaturated fatty acids: a nonrandomized, sequential dietary intervention; the Reading, Imperial, Surrey, Saturated fat Cholesterol Intervention ("RISSCI"-1) study.

Shows: RISSCI-1 sequential exchange lowers average LDL/apoB with marked individual variation.

Does not show: Nonrandomized fixed sequence and biomarker outcomes; the original design must not be called an RCT.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[53] Impact of saturated fat absorption on serum low density lipoprotein-cholesterol response to the replacement of saturated with unsaturated fats in healthy males. The 'Reading, Imperial, Surrey, Saturated fat Cholesterol Intervention-2 (RISSCI-2)' non-randomised sequential dietary intervention study.

Shows: RISSCI-2 repeats response variation and finds absorption does not explain the high/low-response contrast.

Does not show: Participants selected by prior response; shared screening cohort and exploratory mechanism cannot redefine nominal scope.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• ADVERSARIAL_REVIEW.md
• CONSENSUS_CROSSCHECK.html
• CONSENSUS_CROSSCHECK.md
• RESEARCH_TIMELINE.html
• RESEARCH_TIMELINE.md
• SHA256.txt
• adversarial-findings.json
• codex-correction-provenance.json
• consensus-validation.json
• edition-approval-audit.json
• lipid-heart-diet.review.md
• lipid-heart-diet.scorecard.json
• reader-summary.json
• research-timeline.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt
• video-insert.md
• web-page.md

Sources: 53 · load-bearing claims: 57 · verified: 57 · unverified: 0 · contradicted: 0 · schema 5.3